Catalysts for HQ Speciality Pharma
17 tracked
Feb 20, 2026
approval
VABOMERE (MEROPENEM) — FDA approval
HQ Speciality Pharma
→
Jan 19, 2026
approval
AMPICILLIN AND SULBACTAM (AMPICILLIN SODIUM) — FDA approval
UNASYN
→
Jan 19, 2026
approval
AMPICILLIN AND SULBACTAM (AMPICILLIN SODIUM) — FDA approval
UNASYN
→
Dec 11, 2025
approval
MEROPENEM — FDA approval
HQ Speciality Pharma
→
Dec 8, 2025
approval
LINEZOLID — FDA approval
HQ Speciality Pharma
→
Mar 13, 2025
approval
MEROPENEM — FDA approval
HQ Speciality Pharma
→
Dec 3, 2024
approval
VABOMERE (MEROPENEM) — FDA approval
HQ Speciality Pharma
→
Sep 21, 2023
approval
VABOMERE (MEROPENEM) — FDA approval
HQ Speciality Pharma
→
Aug 18, 2022
approval
MEROPENEM — FDA approval
HQ Speciality Pharma
→
May 25, 2020
approval
VABOMERE (MEROPENEM) — FDA approval
HQ Speciality Pharma
→
Nov 16, 2019
approval
AMPICILLIN AND SULBACTAM (AMPICILLIN SODIUM) — FDA approval
UNASYN
→
Jul 6, 2018
approval
VABOMERE (MEROPENEM) — FDA approval
HQ Speciality Pharma
→
Aug 29, 2017
approval
VABOMERE (MEROPENEM) — FDA approval
HQ Speciality Pharma
→
May 1, 2015
approval
AMPICILLIN AND SULBACTAM (AMPICILLIN SODIUM) — FDA approval
UNASYN
→
Aug 5, 2008
approval
AMPICILLIN AND SULBACTAM (AMPICILLIN SODIUM) — FDA approval
UNASYN
→
Jul 16, 2007
approval
AMPICILLIN AND SULBACTAM (AMPICILLIN SODIUM) — FDA approval
UNASYN
→
Nov 30, 2005
approval
AMPICILLIN AND SULBACTAM (AMPICILLIN SODIUM) — FDA approval
UNASYN
→